References
[1] Song L, Zhou Y. The COVID-19 Pandemic and Its Impact on the Global Economy: What Does It Take to Turn Crisis into Opportunity? China World Econ 2020;28:1–25. https://doi.org/https://doi.org/10.1111/cwe.12349.
[2] Pradeep S. Closure of Universities Due to Coronavirus Disease 2019 (COVID-19): Impact on Education and Mental Health of Students and Academic Staff. Cureus 2020;12.
[3] Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open 2021;11:e045343. https://doi.org/10.1136/bmjopen-2020-045343.
[4] Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020;55:105955. https://doi.org/https://doi.org/10.1016/j.ijantimicag.2020.105955.
[5] Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020;4:1178–91. https://doi.org/https://doi.org/10.1002/rth2.12439.
[6] Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 2021;20:172. https://doi.org/10.1186/s12933-021-01359-7.
[7] Bradbury CA, McQuilten Z. Anticoagulation in COVID-19. Lancet 2022;399:5–7. https://doi.org/10.1016/S0140-6736(21)02503-4.
[8] Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID-19: current concepts and controversies. Postgrad Med J 2021:postgradmedj-2021-139923. https://doi.org/10.1136/postgradmedj-2021-139923.
[9] Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology 2020;551:1–9. https://doi.org/10.1016/j.virol.2020.08.011.
[10] Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies . Front Immunol 2020;11.
[11] National Institutes of Health. Corticosteroids | COVID-19 Treatment Guidelines 2022. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/ (accessed March 4, 2022).
[12] The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436.
[13] Cano EJ, Fonseca Fuentes X, Corsini Campioli C, O’Horo JC, Abu Saleh O, Odeyemi Y, et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest 2021;159:1019–40. https://doi.org/10.1016/j.chest.2020.10.054.
[14] Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health 2021;14:570–6. https://doi.org/https://doi.org/10.1016/j.jiph.2021.02.001.
[15] Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ 2021;374. https://doi.org/10.1136/bmj.n1648.
[16] Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ 2021;372. https://doi.org/10.1136/bmj.n136.
[17] Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. JAMA Netw Open 2021;4:e2127403–e2127403. https://doi.org/10.1001/jamanetworkopen.2021.27403.
[18] Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLOS Med 2021;18:e1003773.
[19] Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet (London, England) 2021;398:747–58. https://doi.org/10.1016/S0140-6736(21)01755-4.
[20] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England) 2021;397:220–32. https://doi.org/10.1016/S0140-6736(20)32656-8.
[21] Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open 2021;4:e2111417–e2111417. https://doi.org/10.1001/jamanetworkopen.2021.11417.
[22] Raveendran A V, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr Clin Res Rev 2021;15:869–75. https://doi.org/https://doi.org/10.1016/j.dsx.2021.04.007.
[23] Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med 2021;114:428–42. https://doi.org/10.1177/01410768211032850.
[24] Collaboration GBMIM, Di Angelantonio E, Bhupathiraju S, Wormser D, Gao P, Kaptoge S, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (London, England) 2016;388:776–86. https://doi.org/10.1016/S0140-6736(16)30175-1.
[25] Royal College of Physcians. National Early Warning Score (NEWS) 2 | RCP London 2017. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 (accessed March 9, 2022).
[26] Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. MedRxiv 2020:2020.03.25.20043133. https://doi.org/10.1101/2020.03.25.20043133.
[27] Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med 2020;2:1069–76. https://doi.org/10.1007/s42399-020-00363-4.
[28] Annane D. Corticosteroids for COVID-19. J Intensive Med 2021;1:14–25. https://doi.org/https://doi.org/10.1016/j.jointm.2021.01.002.
[29] Hussain I, Cher GLY, Abid MA, Abid MB. Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential . Front Immunol 2021;12.
[30] Sun Z, Song Z-G, Liu C, Tan S, Lin S, Zhu J, et al. Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med 2022;20:24. https://doi.org/10.1186/s12916-021-02212-0.
[31] Hilpert K, Mikut R. Is There a Connection Between Gut Microbiome Dysbiosis Occurring in COVID-19 Patients and Post-COVID-19 Symptoms? . Front Microbiol 2021;12.
[32] Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AYL, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021;70:698 LP – 706. https://doi.org/10.1136/gutjnl-2020-323020.